


**Technology:** Etanercept is a recombinant tumor necrosis factor receptor ("TNFR"):F<sub>c</sub> fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.



## **Etanercept Timeline** Nov. 1998 Aug. 2016 Apr. 2019 **Enbrel**® Biosimilar Erelzi® **Biosimilar Eticovo® FDA** Approval FDA Approval **FDA** Approval (BL 103795) (aBL 761042) (aBL 761066) (Immunex (Amgen)) (Sandoz) (Samsung Bioepis) Feb. 2016 Aug. 2019 Jun. 2013 Dec. 2014 Sep. 2017 Amgen v. Sandoz Sandoz v. Amgen Amgen v. Sandoz v. IPR2017-02066 (2:16-cv-01118) Amgen (Fed. Cir. 14-1693, Sandoz Petition Filed Decision [Patents Not [Institution (3:13-cv-02904) Appeal of 3:13-cv-02904) (2:16-cv-01118) Invalid; Stipulated Complaint Filed Decision [Affirmed] **Complaint Filed** Denied] Infringement] Apr. 2019 Jul. 2020 Nov. 2013 Aug. 2015 Aug. 2017 Amgen v. Samsung Amgen v. Sandoz Sandoz v. Amgen IPR2015-01792 IPR2017-01916 (Fed. Cir. 20-1037 (3:13-cv-02904) Bioepis Petition Filed **Petition Filed** (2:19-cv-11755) Appeal of 2:16-cv-Motion to Dismiss Granted [Institution [Institution Complaint Filed 01118) Decision Denied] Denied] [Affirmed] **VENABLE** LLP [Ongoing]

	Sandoz v. Amgen 3:13-cv-02904 (N.D. Cal.) Dismissed for lack of subject matter jurisdiction; Fed. Cir. 14-1693 Affirmed	Amgen v. Sandoz 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulation of infringement; Appeal 20-1037 Affirmed, Request for <i>en banc</i> rehearing denied; Supreme Court 20-1110 Certiorari denied	<i>Amgen v. Samsung Bioepis</i> 2:19-cv-11755 (D.N.J.) Ongoing	Coalition for Affordable Drugs v. Amgen IPR2015-01792 Institution denied	Coherus v. Hoffman-La Roche IPR2017-01916 Institution denied	Coherus v. Hoffman-La Roche IPR2017-02066 Institution denied
7,915,225		x	x			
8,063,182	x	x	x			x
8,119,605		x	x			
8,163,522	x	x	x	x	x	
8,722,631		x	x			

